AbbVie announced the U.S. FDA has approved SKYRIZI for adults with moderately to severely active ulcerative colitis, making it the first IL-23 specific inhibitor approved for both moderate to severe ulcerative colitis and moderate to severe Crohn’s disease.3 SKYRIZI is now approved for four indications across immune-mediated inflammatory diseases.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABBV:
- AbbVie Recommends Shareholders Reject Tutanota’s “Mini-Tender” Offer
- AbbVie recommends shareholders reject Tutanota’s ‘mini-tender’ offer
- MRK, ABBV, LI: 3 Low-Beta Stocks with Upside Potential
- AbbVie enters license agreement with FutureGen to develop IBD therapy
- AbbVie’s mirvetuximab soravtansine meets Phase 2 efficacy endpoint